ストックスクリーナーアプリを入手
1.09
1.80%
-0.02
前日終値:
$1.11
開ける：
$1.09
24時間の取引高:
1.73M
Relative Volume:
1.06
時価総額：
$138.64M
収益：
$79.18M
当期純損益:
$-136.99M
株価収益率:
-1.0335
EPS:
-1.0547
ネットキャッシュフロー:
$-120.11M
1週間 パフォーマンス:
+2.83%
1か月 パフォーマンス:
-65.62%
6か月 パフォーマンス:
-72.05%
1年 パフォーマンス:
-64.03%
1日の値動き範囲:
$1.05
$1.1226
1週間の範囲:
$0.9811
$1.13
52週間の値動き範囲:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Compare ADCT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.09 | 138.64M | 79.18M | -136.99M | -120.11M | -1.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 開始されました | Guggenheim | Buy |
| 2023-08-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-04-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 開始されました | CapitalOne | Overweight |
| 2022-11-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-08-17 | 再開されました | Jefferies | Buy |
| 2021-08-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-06-09 | 開始されました | BofA/Merrill | Buy |
| 2020-06-09 | 開始されました | Cowen | Outperform |
すべてを表示
Adc Therapeutics Sa (ADCT) 最新ニュース
Why ADC Therapeutics’ loncastuximab tesirine is still on oncologists’ radar - AD HOC NEWS
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
ADC Therapeutics SA (ADCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ADC Therapeutics SA (ADCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ADC Therapeutics SA (ADCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ADC Therapeutics SA (ADCT) Institutional Confidence - TradingKey
ADC Therapeutics SA (ADCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADC Therapeutics SA (ADCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ADC Therapeutics SA (ADCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ADC Therapeutics SA (ADCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why ZYNLONTA still matters for ADC Therapeutics in a tightening lymphoma market - AD HOC NEWS
ADC Therapeutics SA (ADCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Investors to Learn More About the Investigation | NYSE:ADCT | Press Release - Stockhouse
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Stockholders to Reach Out - ACCESS Newswire
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Stockholders to Connect - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
ADCT Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCLSlideshow - Seeking Alpha
ADC Therapeutics Shares Fall After HC Wainwright Downgrade - marketscreener.com
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday - Benzinga
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA DataHas The Bull Case Changed? - Yahoo Finance
ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursda - Benzinga
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics SA (ADCT) Stock Price, Quote, News & History - Benzinga
Why Is ADC Therapeutics Stock Falling On Friday?ADC Therapeutics (NYSE:ADCT) - Benzinga
Why Is ADC Therapeutics Stock Falling Thursday? - Sahm
ADC Therapeutics’ Zynlonta Clears Phase III PFS Bar But Safety Concerns Cloud FDA Path - Citeline News & Insights
ADCT stock plunges on safety concerns despite positive lymphoma data - MSN
ADCT Downgraded by RBC Capital -- Price Target Lowered to $2.00 - GuruFocus
Zynlonta Lotis position in DLBCL strains ADC shares - BioWorld News
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - Yahoo Finance
ADC Therapeutics plunges after patient deaths in blood cancer drug trial - Reuters
ADC Thera falls on trial data for lymphoma drug (ADCT:NYSE) - Seeking Alpha
RBC Downgrades ADC Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Keeps Speculative Risk - marketscreener.com
An ADC specialist sinks on safety concerns for blood cancer drug - Yahoo Finance
RBC Capital cuts ADC Therapeutics stock rating on trial results By Investing.com - Investing.com UK
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirma - GuruFocus
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma - BioSpace
Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise - Kavout
ADC Therapeutics stock plunges on trial safety concerns - Investing.com
ADC Therapeutics reports positive phase 3 trial results By Investing.com - Investing.com India
ADC Therapeutics stock plunges on trial safety concerns By Investing.com - Investing.com India
Adc Therapeutics Sa (ADCT) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):